Azathioprine Maintains first remission in newly diagnosed pediatric Crohn's disease
β Scribed by Gerald J. Jaspers; Henkjan J. Verkade; Johanna C. Escher; Lissy de Ridder; Jan A. J. M. Taminiau; Edmond H. H. M. Rings
- Book ID
- 110087422
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 176 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background: Thiopurines are considered first-line immunomodulators for the prevention of relapse in moderate to severe pediatric crohn's disease (cd). early introduction of thiopurines was shown in a pediatric trial to maintain steroid-free remission in 90% of patients for 18 months. in the pres
## Background: The effects of azathioprine (AZA) and budesonide (BUD) on mucosal healing and histologic remission of Crohn's disease (CD) are insufficiently studied. In this prospective study we evaluated the comparative effects of AZA and BUD on endoscopic and histologic activity in patients with
## Background: We sought to characterize perianal disease and its treatment in pediatric patients newly diagnosed with crohn's disease. ## Methods: Data were obtained from the pediatric inflammatory bowel disease (ibd) collaborative group registry, a prospective, multicenter observational registr